hit counter
Aceto Corporation (ACET) Stock News Sentiment & Price - Sentifly
ACET - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aceto Corporation (ACET)

USA
Chemicals - Major Diversified
NASDAQ
ACET Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ACET Latest news
GlobeNewsWire
Neutral
CDR-Life Announces Expansion of Scientific Advisory Board
2021-10-26 03:00

Two renowned experts join to advise CDR-Life as the company advances pipeline of novel cancer therapeutic candidates Two renowned experts join to advise CDR-Life as the company advances pipeline of novel cancer therapeutic candidates

GlobeNewsWire
Neutral
Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer
2021-10-12 16:10

MENLO PARK, Calif. and BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced Blake Aftab, Ph.D., has been promoted to the position of Senior Vice President and Chief Scientific Officer. In this role, Dr. Aftab will be responsible for the continued expansion of Adicet's pipeline of therapeutic candidates in solid and hematologic tumors.

GlobeNewsWire
Neutral
Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting
2021-10-04 07:00

MENLO PARK, Calif. and BOSTON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the Company will present data in the form of a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting to be held November 10-14, 2021.

GlobeNewsWire
Neutral
Adicet Bio to Participate in Upcoming Investor Conferences
2021-09-02 16:53

MENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two upcoming virtual investor conferences in September.

Zacks Investment Research
Positive
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Tops Revenue Estimates
2021-08-12 19:19

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 33.33% and 6.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates
2021-08-12 16:01

On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by the end of 2021 On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by the end of 2021

GlobeNewsWire
Neutral
Adicet Bio to Participate in Upcoming Investor Conferences
2021-08-02 07:00

MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in three upcoming virtual investor conferences in August.

GlobeNewsWire
Neutral
Adicet Bio Announces Formation of Scientific Advisory Board
2021-07-15 07:00

MENLO PARK, Calif and BOSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the formation of a Scientific Advisory Board (SAB). The SAB is comprised of renowned scientific leaders in the fields of T cell biology, immunology, and oncology.

GlobeNewsWire
Neutral
Adicet Bio Added to the Russell 2000® Index
2021-06-28 07:00

MENLO PARK, Calif. and BOSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the Company has been added to the Russell 2000® Index, effective June 28, 2021, as part of the 2021 Russell indexes annual reconstitution.

Zacks Investment Research
Negative
Moving Average Crossover Alert: Adicet Bio (ACET)
2021-06-01 07:31

Adicet Bio (ACET) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Loading more news...